Plain-English translation of NCT07261163 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a combination of three medications—, , and —works well as a first treatment for mantle cell lymphoma. All participants will receive the same initial treatment regimen. Depending on how well the disease responds and other risk factors, some patients may also receive an advanced therapy called CAR-T cell therapy, followed by continued maintenance treatment with the medications.
Mantle cell lymphoma is a serious blood cancer that can be difficult to treat. This trial is testing whether combining three drugs together might work better than older treatments, and whether this approach can help more patients achieve long-lasting remission.
You likely qualify if…
You likely don't qualify if…
You will receive the three-medication combination as your first treatment phase. Throughout the study, you'll visit the clinic regularly for blood tests, scans, and physical exams to monitor how well the treatment is working. After the initial treatment, if you are at lower risk, you'll continue taking two of the medications for up to 2 years. If you are at higher risk, you may be referred for CAR-T cell therapy (a specialized treatment using your own immune cells) followed by the same maintenance medications. The study involves about 37 participants across multiple centers in China.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China